Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: Results of a phase II study

Acta Oncologica

Volumn 50, Issue 8, 2011, Pages 1151-1157

  Caravatta, Luciana ^a   Padula, Gilbert D A ^b   Picardi, Vincenzo ^a   Macchia, Gabriella ^a   Deodato, Francesco ^a   Massaccesi, Mariangela ^a   Sofo, Luigi ^a   Pacelli, Fabio ^a   Rotondi, Fabio ^a   Cecere, Giuseppe ^c   Sallustio, Giuseppina ^a   Di Lullo, Liberato ^d   Piscopo, Adele ^a   Mignogna, Samantha ^a   Bonomo, Pierluigi ^a   Cellini, Numa ^e   Valentini, Vincenzo ^e   Morganti, Alessio G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Saint Mary's Health Care   (United States)

^c Surgery Unit   (Italy)

^d General Hospital   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSESTHESIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MICROSCOPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PERIOPERATIVE COMPLICATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTITIS; RADIATION DOSE; RADIATION INJURY; RECTUM CANCER; SIDE EFFECT; TREATMENT RESPONSE; TUMOR BIOPSY; URINARY FREQUENCY; URINE RETENTION; WOUND INFECTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; THIOPHENES;

EID: 80155187117     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.582880     Document Type: Article

References (25)

1. Engel J, Keer J, Eckel R, Günther B, Heiss M, Heitland W, et al. Infl uence of hospital volume on local recurrence and survival in a population sample of rectal cancer patients. Eur J Surg Oncol 2005;31:512-20.
2. Swedish Rectal Cancer Trial (SCRT). Improved survival with preoperative radiotherapy in respectable rectal cancer. N Engl J Med 1997;336:980-7.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable cancer. N Engl J Med 2001;345:638-46.
4. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefi t in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701.
5. Glimelius B. Pre- or postoperative radiotherapy in rectal cancer - more to learn? Radiother Oncol 2001;61:1-5.
6. Sauer R, Becker H, Hohenberg W, Röd el C, Wittekind C, Fietkau R, et al. German Rectal Cancer Study Group. Preoperative vs. postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
7. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009;92:148-63.
8. Allal AS, Bieri S, Bründler MA, Soravia C, Gertsch P, Bernier J, et al. Preoperative hyperfractionated radiotherapy for locally advanced rectal cancers: A phase I-II trial. Int J Radiat Oncol Biol Phys 2002;54:1076-81.
9. Bosset JF, Collette L, Calais G, Berger C, Radosevic-Jelic L, Maingon P, et al. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
10. Gerard J, Bonnetain F, Conroy T, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperatory radiotherapy with or without concurrent fl ourouracil in T3-4 rectal cancers: Results of the FFCD 9203. J Clin Oncol 2005;24:4620-5.
11. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin and radiation for rectal cancer. J Clin Oncol 2003;21: 3098-104.
12. Gambacorta MA, Valentini V, Coco C, Morganti AG, Smaniotto D, Miccich è F, et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int J Radiat Oncol Biol Phys 2004;60:139-48.
13. Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Marone P, et al. Biweekly oxaliplatin, raltitrexed, 5-fl uorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: A phase I-II study. Br J Cancer 2006;94:1809-15.
14. Valentini V, Coco C, Minsky BD, Gambacorta MA, Cosimelli M, Bellavita R, et al. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: Raltitrexed oxaliplatin radiotherapy versus cisplatin 5-fl uorouracil radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:403-12.
15. Picardi V, Caravatta L, Morganti AG, Macchia G, Deodato F, Tambaro R, et al. Accelerated radiotherapy (concomitant boost) plus concurrent chemotherapy in neoadjuvant treatment of advanced rectal cancer: Preliminary results of a phase I study. Tumori 2008;(Suppl 7):8.
16. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al., editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
17. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53.
18. Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, et al. Defi nition and delineation of the clinical target volume for rectal cancer. Int J Radiat Onol Biol Phys 2006;65:1129-42.
19. International Commission on Radiation Units and Measurements, ICRU report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda: ICRU; 1999.
20. Luna-P é rez P, Trejo-Valdivia B, Labastida S, García- Alvarado S, Rodr íguez DF, Delgado S. Prognostic factors in patients with locally advanced rectal adenocarcinoma treated with preoperative radiotherapy and surgery. World J Surg 1999;23:1069-74.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
22. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
23. Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 14S: 6098.
24. G é rard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial. J Clin Oncol 2003;21:1119-24.
25. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: Longer analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008;72:99-107.